Mytos announces strategic partnerships with StemSight, Rinri Therapeutics, and Novadip to power next-generation cell therapy trials.

Mytos’ automated cell culture technology will power manufacturing of dopaminergic neuronal precursor cells for Aspen’s investigational cell therapy ANPD001 in Parkinson’s diseaseLONDON–(BUSINESS WIRE)–#automation—Mytos, an innovative leader in automated cell manufacturing, has entered into a manufacturing collaboration with Aspen Neuroscience, Inc. to automate the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs) for ANPD001, Aspen’s investigational cell therapy program for Parkinson’s disease (PD).The DANPCs, designed to replace lost dopamine-producing neurons in the brain, are differentiated from induced pluripotent stem cells (iPSCs), which are derived from the patient’s own skin cells. This approach holds the promise of restoring lost function without the need for immunosuppressive drugs.As part of the partnership agreement, Aspen will integrate Mytos’ iDEM automated cell culture technology into its new manufacturing facility in Torrey Pines, Calif. The iDEM automated cell culture technology combines fluidics, advanced imaging, and mechanical movement and control to enable fully hands-off production of specific human cell types. This agreement represents the potential for substantial payments to Mytos over the coming years.Mytos’ automation has the potential to drive substantial improvements in efficiency and scalability. By closing and automating processes, iDEM empowers operators to manage more batches simultaneously within a smaller cleanroom footprint, minimizing the need for extensive hiring, training, and facility expansions as manufacturing scales out.“We are excited to work with the innovative Mytos team